On January 5, 2021 Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, reported that the Company’s management team will present and host meetings with investors and potential partners next week at the H.C. Wainwright BioConnect Conference, J.P. Morgan Healthcare Conference and 23rd Annual ICR Conference being held virtually between January 11-14, 2021 (Press release, Humanigen, JAN 5, 2021, View Source [SID1234573513]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will provide an update on enrollment for its Phase 3 clinical trial of lenzilumab in patients hospitalized with COVID-19, an update on the commercial preparation ahead of a potential Emergency Use Authorization (EUA) for lenzilumab as well as an overview of the Company’s other programs.

Details for the upcoming virtual investor conferences are below:

H.C. Wainwright BioConnect Conference

Date: Monday, January 11, 2021
Presentation Viewable Starting at 6:00 AM ET
Event Link:
View Source

J.P. Morgan Healthcare Conference

Date: Wednesday, January 13, 2021
Presentation Time: 8:20 AM ET
Event Link:
View Source;kiosk=true

2021 ICR Conference

Date: Thursday, January 14, 2021
Fireside Chat with Cosme Ordonez, National Securities: 1:00 PM ET
Event Link:
https://icrinc.touchcast.com/showtime/icr-conference/embed/19b8209f-86ae-93a7-6351-107304d2f9d0

On January 5, 2021 Kaleido Biosciences, Inc., (Nasdaq: KLDO) reported that Dan Menichella, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. EST on Thursday, Jan. 14, 2021 (Press release, Kaleido Biosciences, JAN 5, 2021, View Source [SID1234573463]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation and question and answer session can be accessed on the Investors & Media section of the Kaleido website at View Source An archived replay will be accessible following the event.

On January 5, 2021 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage company focused on making a positive impact on patients’ lives, reported that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will present at three upcoming virtual conferences (Press release, Cytori Therapeutics, JAN 5, 2021, View Source [SID1234573481]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event H.C. Wainwright BioConnect Conference
Date January 11-14, 2021
Time Presentation available on demand January 11-14, 2021

Event Biotech Showcase 2021
Date January 11-15, 2021

Event ICR Conference 2021
Date Thursday, January 14, 2021
Time 1:45 p.m. ET
Investors interested in arranging a meeting with the Company’s management during the ICR Conference 2021 should contact the conference coordinator or [email protected]. Webcasts of the H.C. Wainwright and ICR conferences presentations will be available under the ‘Events’ tab of the Investor Relations section of the Plus Therapeutics website at www.plustherapeutics.com.

On January 5, 2021 EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in robotic energy based therapies, reported that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021 (Press release, EDAP TMS, JAN 5, 2021, View Source [SID1234573498]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Marc Oczachowski, President and CEO, will host 1×1 meetings and will present a corporate update on Thursday, January 7th at 9am EST/ 2pm GMT /3pm CET.

To register to listen to the presentation or to request a meeting, visit: View Source To access the subsequent archived recording of this presentation, please visit the Investor Relations section of the EDAP website or click here.

On January 5, 2021 Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, reported that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the virtual 39th Annual J.P. Morgan Healthcare Conference at 3:40 p.m. ET on Tuesday, January 12, 2021 (Press release, Ionis Pharmaceuticals, JAN 5, 2021, View Source [SID1234573514]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Investors & Media section of the Ionis website. The replay will be available within 48 hours and archived for a limited time.